spacer
home > pmps > autumn 2008 > silicon syringes
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Silicon Syringes

Pre-filled syringes have for a number of years been the focus of the parenteral drug developer and they are there to stay. They have enjoyed tremendous market development, a process that has not yet come to an end. While Europe traditionally took the largest share of prefilled syringe applications, the US market is now quickly catching up at a considerable pace. Numbers may depend on the source, but the total worldwide market for prefilled syringes has been estimated as three billion in 2010. Growth rates for prefilled syringes are still double-digit numbers. Syringes in glass have an established position, seeing a yearly growth rate of 10 per cent; for plastic syringes that, relative to glass, are at the start of their market acceptance, numbers of 20 per cent are quoted.

The rapid development of prefilled syringes is founded on numerous factors. Among the most important of these are its dose accuracy, its low dead volume – which, especially for expensive biotech drugs, leads to considerable savings – the possibility to extend the product life cycle of a drug and to offer pharmaceutical product differentiation, and of course the convenience and ease of use for medical personnel. Another reason that is related to the market is the advent of more biologicals in the R&D pipelines of major drug companies – biologicals that can only be administered via a parenteral route.

Many things can be said about prefillable syringes, and it is impossible to be exhaustive. Therefore, this article will deal with some more topical discussions, with particular focus on the siliconisation of syringes or of syringe components.

WHY SILICONISATION?

In order to be functional – that is, to deliver a drug dose to a patient in a correct and adequate way – two components of prefilled syringes typically are siliconised...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Renaud Janssen graduated as a chemical engineer from Leuven University, Belgium. After finishing his doctoral study, he joined Janssen Pharmaceutica, where he worked in the Department of Chemical Development and Production. In 1988 he joined Helvoet Pharma, where he has held various functions in R&D, technical support and quality. Renaud is currently heading Helvoet Pharma’s global department of Technical Support.
spacer
Dr Renaud Janssen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo awarded with the prestigious Cargo Airline of the Year 2019 prize by the global logistics industry

 Maintaining its upward trend, Turkish Cargo was granted with the ‘Cargo Airline of the Year 2019’ award, called as the Oscar of the global logistics industry, by the global air cargo sector readers of the Air Cargo News magazine.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement